- Patients who received ubrogepant for treatment of migraine had greater pain relief and decrease in the most bothersome migraine symptoms at 2 hours than those who received a placebo.
Why this matters
- This study confirms earlier research that found ubrogepant to be effective at treating acute migraine.
- This randomized, double-blind, parallel-group trial evaluated the efficacy, safety, and side-effect profile of ubrogepant in patients with a history of migraine (≥1 year).
- Treatment received: placebo (n=456), 50-mg ubrogepant (n=423), or 100-mg ubrogepant (n=448).
- Funding: Allergan.
- The number of participants with freedom from migraine pain at 2 hours:
- placebo group, 11.8%;
- 50-mg ubrogepant group, 19.2% (vs placebo; OR, 1.83; Padjusted=.002); and
- 100-mg ubrogepant group, 21.2% (vs placebo; OR, 2.04; Padjusted<.001>
- Absence of the most bothersome symptom at 2 hours:
- placebo group, 27.8%;
- 50-mg ubrogepant group, 38.6% (vs placebo; OR, 1.70; Padjusted=.002); and
- 100-mg ubrogepant group, 37.7% (vs placebo; OR, 1.63; Padjusted=.002).
- Any adverse events reported:
- placebo group, 12.8%;
- 50-mg ubrogepant group, 9.4%; and
- 100-mg ubrogepant group, 16.3%.
- Most common adverse events reported within 48 hours were nausea, somnolence, and dry mouth.
- Limited generalizability.
Coauthored by Chitra Ravi, MPharm